Goldman Sachs’s Indaptus Therapeutics INDP Stock Holding History

Goldman Sachs’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-238	Closed	-$116K	–	6356
2021 Q1	$116K	Sell	238 -12	-5%	-$6.29K	﹤0.01%	5797
2020 Q4	$97K	Buy	+250	New	+$109K	﹤0.01%	5299
2019 Q3	–	Sell	-6	Closed	-$62K	–	5267
2019 Q2	$62K	Buy	+6	New	+$75.7K	﹤0.01%	4999

Other funds holding INDP

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Goldman Sachs's INDP Position: Q2 2021 in Review

Goldman Sachs sold out of Indaptus Therapeutics (INDP) in Q2 2021, closing a stake of 238 shares — an estimated $116K sold.

Goldman Sachs first reported a position in INDP in Q2 2019 and held it in 3 quarters. The position peaked at $116K in Q1 2021. 10 funds tracked by Wall St. Rank hold INDP as of Q2 2021.

Goldman Sachs reported no remaining Indaptus Therapeutics position as of Q2 2021 after selling out during the quarter.
Goldman Sachs sold 238 Indaptus Therapeutics shares in Q2 2021, an estimated $116K.
Goldman Sachs first reported a position in Indaptus Therapeutics in Q2 2019 and held it in 3 quarters.
Goldman Sachs's Indaptus Therapeutics position peaked at $116K in Q1 2021.
10 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.